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Rapid Genotyping of the Five Major Platelet Alloantigens by Reverse Dot-BIot Hybridization
By Paul F. Bray, Ying Jin, and Thomas Kickler Amino acid substitutions in platelet membrane glycoproteins result in alloantigens. Identifying these polymorphisms is important in alloimmune-mediated platelet disorders. Immunophenotyping platelet antigens can be limited by the unavailability of specific antisera. The goal of this work was to identify human platelet antigen genotypes in individuals using a technique that would circumvent the limitations of immunophenotyping and be clinically applicable. We have successfully applied the reverse dot-blot (RDB) technique to the genotyping of the five major human platelet alloantigen systems. Allele-specific oligonucleotides (ASOsl representing each allele of these alloantigens were covalently linked to a filter. Biotinylated oligonucleotides flanking the polymorphic sequences in genomic DNA were used to amplify LLOIMMUNE-MEDIATED platelet destruction by antibodies to platelet-specific antigens may be seen in at least three well-known clinical entities.'.2 These entities include neonatal alloimmune thrombocytopenia, posttransfusion purpura, and refractoriness to platelet transfusions. These conditions require detailed serologic analysis for immunophenotyping as well as the identification of antibodies directed at specific antigens. In neonatal alloimmune thrombocytopenia (NAIT), pregnant women may become immunized to fetal platelet alloantigens, resulting in thrombocytopenia in the infant.3 This disorder differs from Rh hemolytic disease of the newborn by occumng during the first pregnancy. Routine screening is not performed to identify women at risk, although this has been recommended as a means of preventing serious complication^.^ The PIA system was the first recognized platelet-specific alloantigen implicated in NAIT, 3 and maternofetal incompatibility for PIA antigens accounts for more than 90% of reported cases of NAIT as well as most cases of posttransfusion purpura (FTP).' Other important antigen systems incriminated in NAXT include Br, B&, Pen, and Ko.'-~ Excellent reviews exist on the immunology, genetics, and nomenclature of these systems.","
The current method for determining an individual's platelet alloantigen phenotype is by immunophenotyping, whereas antibody detection is dependent on measuring bound antibody to a panel of typed platelets.'* These methods both require the availability of two crucial reagents: wellcharacterized typing sera and a panel of phenotyped donors, Relatively few laboratories have adequate typing sera available for the many specificities required to characterize the identity of different platelet alloantibodies. A major problem with the identification of alloantibodies can be the presence of coexisting HLA antibodies.12 Finally, there are times when the thrombocytopenia is so severe at presentation that it is not possible to obtain enough platelets to serologically type.
The DNA polymorphisms responsible for each of the five major platelet alloantigen systems have now been identiand are summarized in Table 1 . In all cases, a single nucleotide substitution results in an amino acid change that, in turn, alters the antigenicity of the glycoprotein. Genotyping is not limited by any of the problems associated with platelet immunophenotyping. We have therefore applied the reverse dot-blot (RDB) techniq~e'~.~' to the genotyping of A fied"-I8 the major platelet alloantigens. We now report that this procedure can be performed accurately and rapidly (<24 hours) on both blood and fetal amniocytes. This approach should greatly complement the immunophenotyping data and, in some cases, may replace it. Moreover, this approach will allow the development of screening programs for the identification of fetuses at risk for thrombocytopenia. 
MATERIALS AND METHODS

Reagents
Oligonucleotides
Polymerase chain reaction (PCR) oligonucleotides were designed from published genomic DNA sequences2124 and synthesized on an Applied Biosystems (Foster City, CA) DNA synthesizer. Aminolinked allele-specific oligonucleotides (ASOs) were 15 to 18 bp in length and differed by the single nucleotide that bas been shown to cause the polymorphic amino acid."^'* Amino groups and biotin (Applied Biosystems) were added to the 5' end of the appropriate oligonucleotide. Each biotinylated primer pair (listed in 
DNA Samples and Preparation
Whole blood from normal volunteers and patients with thrombocytopenia and cultured amniocytes from a fetus at risk for neonatal thrombocytopenia were used to isolate genomic DNA. A number of samples were kindly provided to us: Pen& and Penbm blood by Prof Y. Shihata (Tokyo, Japan); KO"/" DNA by Janice McFarland (Milwaukee, WI); and Koa DNA by Gail Teramino (Puget Sound Blood Center, Seattle, WA). Whole blood (0.5 mL) was added to an equal volume of PCR lysis buffer (PLB; 0.32 molL sucrose, IO mmom Tris [pH 7.51, 1% Triton X-100, 5 mmoUL MgCI2). Fetal amniocytes were initially resuspended in 1 mL of PLB. Samples were centrifuged for 20 seconds at 13,OOOg, the pellet was resuspended in 1 mL PLB, and this process was repeated two times. The pellet was resuspended in 0. 
RDB Procedure
Membrane preparation. Biodyne C membranes (Pall Biosupport, East Hills, NY) were rinsed in 0.1 N HCI, rinsed in water, incubated in 10% (0.52 mom) EDC for 15 minutes, at room temperature, rinsed in water and allowed to air dry. Amino-linked ASOs were diluted to 5 p m o l / p L with 0.5 m o m NaHC03/Na2C03 buffer, pH 8.4, and 2 pL was carefully applied to a filter and allowed to dry for 15 minutes. Membranes were then rinsed once in 0.1 N NaOH for 1 minute, rinsed three times in water, and allowed to dry. This procedure covalently linked each AS0 to the filter. We have successfully used filters that were prepared 2.5 months earlier (stored at room temperature), but they may be used for at least 6 months (Jeff Wold, personal communication, October 1993).
Hybridizing and washing. Two hundred nanograms of genomic
DNA was amplified in a 50 pL PCR reaction with the biotinylated primers, as previously described." In all cases, positive control DNAs for each antigen system were used. For each set of PCR primers, a negative control consisting of no template DNA in the PCR reaction was always performed to assure no products were amplified from potentially contaminating DNA. In some cases, two or three primer pairs were used in a single PCR reaction. Twentyfive to thirty microliters of each PCR reaction from a single individual was added to 15 mmoUL trisodium citrate, pH 7.0)/0.1% sodium dodecyl sulfate (SDS) in a polypropylene tube. The membrane is added, the tube is boiled for 5 minutes to denature the PCR products, and the tube is immediately transferred to a shaking 45°C water bath for 1 hour or more. 
Immunophenotyping
Immunophenotyping was performed using a radiolabeled antiglobulin test described by Cines and SchreibeZ6 and adapted for platelet typing." Control antisera used to type platelets have been obtained from our patients (anti-PIA', PIAZ, -B e , -Bakb, -BP) or supplied by Drs Y. Shihata (anti-Pen", -Penb, BP, -Brb) and F. Ishida (anti-KO"). Exchange with other laboratories has confirmed the specificity of our antisera as typing reagents. antisera and lysed in Triton X-100. After centrifugation at 12, OOOg, the suspension is applied to microtiter wells coated with monoclonal antibodies specific for GPIIb, GPIIIa, and GPIb (from Amac, Inc, Westbrook ME). The amount of human IgG in the test antisera bound to each platelet glycoprotein is measured by incubating with the F(ab')' fraction of biotinylated goat antihuman IgG (Chemicon, Temecula, CA), washing, adding p-nitrophenylpbosphate and streptavidin conjugated to alkaline phosphatase, and measuring the absorbance at 405 nm in a microplate reader (Biotek, Winooski, VT).
Monoclonal Antibody Capture Enzyme-Linked Imrnunosorbent Assay (MACE)
Establishing Panel of Controls
Control DNAs for the RDB analysis were identified by both immunophenotyping and DNA analysis or just by DNA analysis. For the DNA analysis, PCR products were either directly sequencedz6 or restriction-digested using the enzymes Hga I, Fok I, and Mnl I, which distinguish the homozygous or heterozygous state for
KO,
Bak, and Br, re~pectively.~~~'~ As mentioned above, these controls were used with all analyses to eliminate false-negatives caused by reagent failure or execution problems.
RESULTS
A series of preliminary studies were performed to establish the correct conditions for this assay. The first essential aspect of this work was to develop a panel of control DNA samples from individuals representing all three combinations of alleles (2 homozygous samples and 1 heterozygous sample) for all five antigen systems. Controls were identified by both immunophenotyping and DNA analyses (either restriction endonuclease digestion or direct nucleotide sequencing of PCR products). Because there were not specific antisera available to us for all homozygous states, only those tested are shown in Fig 2. The panel of controls is shown in Fig  2 and demonstrates that the RDB results are consistent with the immunologic and nucleotide sequence information.
The second body of preliminary work was to define ASOs for detection of each of the various genotypes.
Initially, we generated biotinylated PCR primers flanking the known areas of the genome that contained the polymorphism resulting in each antigen system (data not shown). We arbitrarily chose hybridization conditions that allowed the accurate detection of the two PIA alleles and then required the remaining eight ASOs to correctly hybridize under these same conditions. Specifically, we hybridized in 2~ SSC/O.I% SDS at 45°C and washed in 0.5X SSC/O. 1% SDS at 42°C. We then synthesized ASOs for the KO, B&, Pen, and Br systems that specifically reacted with their corresponding amplified PCR products under these same conditions. Eventually, ASOs, hybridization, and washing conditions were determined that permitted successful genotyping in a single hybridization. These RDB results were consistent with both the immunophenotyping and the nucleotide sequence analysis (data not shown).
Having established the specificity of the RDB for the five major platelet alloantigens, we tested its utility in clinical situations of alloimmune thrombocytopenia. We obtained blood from women who had previously delivered a baby with neonatal alloimmune thrombocytopenia and also from their husbands. Genomic DNA from these individuals was prepared and hybridized to membranes that had been prepared days in advance (Fig 3) . These results supported the previous immunophenotyping and antibody identification results that indicated an anti-PIA' antibody in the first two couples. The limited immunophenotyping data on the third couple did not permit identification of the immunizing antigen, whereas the RDB analysis proved Br incompatibility. Similarly, we tested a patient with posttransfusion purpura (PTP) caused by an anti-PIA' antibody and showed the PlA2 homozygous state (Fig 4) . These data show the genetic basis for platelet antigen incompatibility, thus providing an explanation for the presence of these patient's antiplatelet antibodies.
We also analyzed a family in which the mother had had a previous episode of FTP and who became pregnant. Maternal serum was tested in our MACE assay against six different sets of platelet GPs (data not shown). It was always negative for antibodies to GPIIb, GPIIIa, and GPIb-IX. It was negative for GPIaAIa in 5 of the platelet samples tested and positive in 1. Because Br is a relatively uncommon cause of PTP, we sought supportive immunologic evidence that this was the offending platelet antigen system. The maternal serum was tested against the husband's platelet GPIa and yielded a "borderline" result. We were not able to test maternal serum against known Br" homozygous platelets because we do not have such a sample (most laboratories would not, and the lack of the very rare homozygous Bra phenotype underscores the value of genotyping in these cases). In sum, these immunophenotyping data support the notion that the mother in this case had an anti-BP antibody, with the MACE being positive against I d I a only 1 of 6 tests because of the low frequency of BP. Both she and her husband had identical genotypes for the five systems tested except for Br, in which she was homozygous BP and he was heterozygous BPIBP (Fig 5A) . Therefore, we felt that the fetus was at risk for NAIT should he/she inherit the father's Brb allele. Consequently, when an amniocentesis was performed for age-related reasons, we obtained fetal amniocytes, extracted genomic DNA, and used RDB analysis to genotype the fetus ( Fig  SA) . The fetus proved to be Brb/BP and is therefore not at risk for NAIT for this antigen system. To provide additional support for a Glu to Lys substitution at amino acid 505 of GPIa, we digested the PCR products with the restriction enzyme Mnl I (Fig 5B) , which can distinguish between the 2 homozygous states and 1 heterozygous state.24 These results confirmed that the fetus was homozygous Brb/Brb. The mother most likely had been transfused with blood that contained the BP antigen, inducing an antibody response to this relatively less-common antigen.
DISCUSSION
We have successfully applied the technique of RDB analysis to genotype the five major platelet alloantigen systems. This method is simple, rapid, and accurate and was useful in characterizing cases of NAIT and PTP. AS0 hybridization has been used to detect single-base changes at a specific location in the genome.30 Because the AS0 was labeled with 32P, this method has traditionally been confined to the research laboratory. The RDB technique is a nonradioactive PCR-based methodology for the rapid identification of specific alleles that differ by a single nucleotide.'' It has been successfully used for genotyping in the prenatal diagnosis of thalassemia3' and cystic fibrosis." It is similar to the above described AS0 hybridizations except that it is "reversed," use only. ie, the AS0 is fixed to the filter and the PCR products are in the hybridization solution. Because the ASOs are previously applied to the membranes, the entire procedure can be performed in 1 day (DNA extraction, 1 hour; PCR reaction, 2 to 3 hours; hybridization, 1 to 2 hours; washing and color development, 1 hour; total, -6 hours). Finally, we have been able to obtain enough DNA for these analyses from as little as 5 pL of whole blood and from fetal amniocytes.
During the course of our studies, we experienced problems with reliability of typing sera and availability of platelets, prohibiting an accurate and comprehensive immunologic characterization. The most reliable methods for detecting alloantibodies measure antibody binding to a panel of typed platelets. This measuring requires the availability of wellcharacterized typing sera and a panel of phenotyped donors. Well-characterized antisera is not commercially available. Therefore, laboratories must obtain their own or obtain them Reverse Dot Blot from other investigators. In addition, relatively few laboratories have all the typing sera required to characterize the plethora of different platelet alloantibodies. This is particularly important for a patient who is heterozygous and typing sera is only available for one of the polymorphisms. For these diallelic loci, proof of heterozygosity eliminates that antigen system as a possible stimulus for antibody formation, and the appropriate genetic counseling can be administered. Another major problem with the identification of alloantibodies can be the presence of coexisting HLA antibodies.'' It is also difficult to distinguish an antibody to a high-incidence platelet alloantigen from an autoantibody that also reacts with all platelets tested. Immunoblotting or the use of monoclonal glycoprotein capture assays can be used to circumvent some of these problems,'X but not always conclusively. Another issue complicating the identification of antibodies is the growing number of antigens (many of which are low use only. incidence) that have been described. Also, frequently the thrombocytopenia is so severe at presentation that it is not possible to obtain enough platelets to immunophenotype. Other problems can occur, such as low titer antibodies and the disappearance of the antibody over time. Attempts to overcome these problems have generally been handled by using combinations of assays, but equivocal results may still occur. Genotyping is not limited by these problems and would be an extremely useful complement to serologic studies. Genotype information indicates which alloantigen systems are incompatible, ie, those for which an antibody could theoretically be generated. Note that, in Fig 3, for example, the couple RM and FM are potentially "incompatible" for the PI", KO, and Br systems. Other immunology studies must be performed to determine the presence and specificity of an antibody. Nevertheless, for the reasons listed above, we believe that genotyping rather than immunophenotyping is a more accurate and reliable method for determining the antigen status of both normal and patient populations.
There are a number of effective methods that have been used to genotype patients for single nucleotide changes in genomic DNA, each with its own advantages. McFarland et aI3' used a nonradioactive variation of AS0 hybridization to genotype families with a history of NAIT. These ASOs were identical with each other except for the single nucleotide difference at the polymorphic site, which provided a 100% correlation with serologic typing for either PI"' or PI"' . Simsek et al'" have used another PCR-based technique to geno- type 98 Dutch blood donors for PI", KO, and Bak. They PCR-amplified genomic DNA containing the polymorphic region, restriction-digested the products with an enzyme that cut one allele but not the other, and analyzed these products on agarose gels. More recently, Metcalfe and Waters" used allele-specific primers in a PCR amplification to test individuals for their PI" genotype. Although only used for one antigen system, this method was simple, rapid, and accurate.
All of these genotyping techniques have the advantages of (1) speed, (2) circumventing the need for specific typing sera. and (3) not requiring a certain number of platelets that can often be difficult to obtain. Each technique has certain disadvantages as well, such as a large number of hybridizations,3' the use of restriction enzymes,lY electrophoresis,2".3' and two PCR reactions for each antigen systemJ3 The use of restriction enzymes introduces a potential for error with both incomplete digestion and overdigestion of the DNA. In addition, not all polymorphisms will be amenable to this technique because they may not alter a restriction enzyme site. result is made by always amplifying our positive control DNA samples for each of the IO alleles tested. In addition, because our PCR primers are able to amplify both alleles of all five antigen systems (Fig 2) , a heterozygous genotype result would not be mistaken for a homozygous one. That is, as long as one of the two "dots" were positive, the only potential source of error concerning the negative A S 0 was if that A S 0 had inadvertently not been applied to the membrane. For this reason, whenever the putative offending antigen was detected, the analysis wils repeated with a new "strip" to rule out the possibility of an error when spotting the ASO.
There are several other platelet-specific antigens that have been described" and an increasing number of antibodies to these antigens have been reported. Many of these appear to be directed against private or low incidence alloantigens. The characterization of these antigens is limited by the unavailability of antisera and methods for detection and specific identification. Once the nucleotide substitution responsible for these rare polymorphisms has been identified, testing for them could easily be added to the five we have performed.
Accurate characterization of an individual's platelet alloantigens in the immune-mediated thrombocytopenias is Note that the analysis on the fetus was identical to that on the mother (CVC).
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needed so that ( I ) the most appropriate therapy can be administered, (2) genetic counseling can be given, (3) factors involved in their pathogenesis can be studied. and (4) comprehensive screening programs for obstetric patients can be developed. The development of reliable antenatal testing and effective therapies for hemolytic disease of the newborn has dramatically improved the survival of fetuses at risk for Rh disease.34 Similar advances are needed in NAIT. The RDB is a rapid, accurate, and sensitive assay that can easily be applied to a clinical laboratory that would identify women at risk for being alloimmunized.
